Compare FLUX & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLUX | KALA |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9M | 13.3M |
| IPO Year | 2019 | 2017 |
| Metric | FLUX | KALA |
|---|---|---|
| Price | $0.55 | $0.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | ★ 374.7K | 364.1K |
| Earning Date | 05-07-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.00 | ★ 67.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,317,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.01 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 126.25 | N/A |
| 52 Week Low | $0.47 | $0.07 |
| 52 Week High | $7.55 | $19.77 |
| Indicator | FLUX | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 42.40 | 36.00 |
| Support Level | $0.50 | $0.51 |
| Resistance Level | $0.63 | $0.72 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 15.95 | 18.67 |
Flux Power Holdings Inc. designs, develops, manufactures, and sells a portfolio of lithium-ion energy storage solutions for the electrification of a range of industrial and commercial sectors, which include material handling, airport ground support equipment (GSE), and stationary energy storage. It offers a high-power battery cell management system(BMS). The BMS serves as the brain of the energy storage solution, managing cell balancing, charging, discharging, monitoring, and communication between the pack and the forklift. The company's product portfolio includes Battery Technology and Energy Management solutions.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.